J Dent Anesth Pain Med.  2016 Jun;16(2):89-94. 10.17245/jdapm.2016.16.2.89.

Current trends in intravenous sedative drugs for dental procedures

• Yoon JY
• Kim EJ

• KMID: 2328850
• DOI: http://doi.org/10.17245/jdapm.2016.16.2.89

Abstract

Anxiety and phobia in dental procedures are common deterrents for patients visiting the dental care unit. For these individuals, procedural sedation may aid in completion of dental treatments. In most cases, the patients are conscious during sedation, thereby allowing spontaneous ventilation. Intravenous sedation (IVS) is widely used during dental treatment to relieve patient anxiety. IVS is the most effective route of administration to achieve this goal, but it requires advanced training, more than that provided during undergraduate education. During IVS, rapid onset, repetitive drug administration, easy titration, and rapid recovery from sedation can be achieved. However, conscious sedation during IVS can result in deep sedation that can cause respiratory and cardiovascular depression. Therefore, the characteristics of intravenous sedatives should be known. The purpose of this review is to discuss the characteristics and usage of intravenous sedatives currently used for dental procedures.

Keyword

Conscious Sedation; Dentistry; Intravenous Anesthetics; Dentistry

MeSH Terms

Anesthetics, Intravenous
Anxiety
Conscious Sedation
Deep Sedation
Dental Care
Dentistry
Depression
Education
Humans
Hypnotics and Sedatives
Phobic Disorders
Ventilation
Anesthetics, Intravenous
Hypnotics and Sedatives

Reference

1. Coolidge T, Irwin SP, Leyster KA, Milgrom P. Determinants of receiving intravenous sedation in a sample of dentally-fearful patients in the USA. SAAD Dig. 2012; 28:52–60.

2. Sago T, Harano N, Chogyoji Y, Nunomaki M, Shiiba S, Watanabe S. A nasal high-flow system prevents hypoxia in dental patients under intravenous sedation. J Oral Maxillofac Surg. 2015; 73:1058–1064.

3. Standing Dental Advisory Committee. Conscious sedation in the provision of dental care: New guidelines. SAAD Dig. 2004; 21:20–22.

4. Ikeda H, Ayuse T, Oi K. The effects of head and body positioning on upper airway collapsibility in normal subjects who received midazolam sedation. J Clin Anesth. 2006; 18:185–193.

5. Urman RD, Punwani N, Shapiro FE. Patient safety and office-based anesthesia. Curr Opin Anaesthesiol. 2012; 25:648–653.

6. Winsky-Sommerer R. Role of GABAA receptors in the physiology and pharmacology of sleep. Eur J Neurosci. 2009; 29:1779–1794.

7. Zacharias M, Hunter KM, Luyk NH. Patient-controlled sedation using midazolam. Br J Oral Maxillofac Surg. 1994; 32:168–173.

8. Coulthard P, Sano K, Thomson PJ, Macfarlane TV. The effects of midazolam and flumazenil on psychomotor function and alertness in human volunteers. Br Dent J. 2000; 188:325–328.

9. Allonen H, Ziegler G, Klotz U. Midazolam kinetics. Clin Pharmacol Ther. 1981; 30:653–661.

10. Greenblatt DJ, Divoll M, Abernethy DR, Locniskar A, Shader RI. Pharmacokinetics of benzodiazepine hypnotics. Pharmacology. 1983; 27:Suppl 2. 70–75.

11. Golparvar M, Saghaei M, Sajedi P, Razavi SS. Paradoxical reaction following intravenous midazolam premedication in pediatric patients - a randomized placebo controlled trial of ketamine for rapid tranquilization. Paediatr Anaesth. 2004; 14:924–930.

12. McKenzie WS, Rosenberg M. Paradoxical reaction following administration of a benzodiazepine. J Oral Maxillofac Surg. 2010; 68:3034–3036.

13. Martin G, Glass PS, Breslin DS, MacLeod DB, Sanderson IC, Lubarsky DA, et al. A study of anesthetic drug utilization in different age groups. J Clin Anesth. 2003; 15:194–200.

14. Krasowski MD, Nishikawa K, Nikolaeva N, Lin A, Harrison NL. Methionine 286 in transmembrane domain 3 of the GABAA receptor beta subunit controls a binding cavity for propofol and other alkylphenol general anesthetics. Neuropharmacology. 2001; 41:952–964.

15. Swanson ER, Seaberg DC, Mathias S. The use of propofol for sedation in the emergency department. Acad Emerg Med. 1996; 3:234–238.

16. Hughes MA, Glass PS, Jacobs JR. Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. Anesthesiology. 1992; 76:334–341.

17. Jalota L, Kalira V, George E, Shi YY, Hornuss C, Radke O, et al. Prevention of pain on injection of propofol: Systematic review and meta-analysis. BMJ. 2011; 342:d1110.

18. McNeir DA, Mainous EG, Trieger N. Propofol as an intravenous agent in general anesthesia and conscious sedation. Anesth Prog. 1988; 35:147–151.

19. Miner JR, Burton JH. Clinical practice advisory: Emergency department procedural sedation with propofol. Ann Emerg Med. 2007; 50:182–187. 187.e1

20. Jacobi J, Fraser GL, Coursin DB, Riker RR, Fontaine D, Wittbrodt ET, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med. 2002; 30:119–141.

21. Green SM, Roback MG, Kennedy RM, Krauss B. Clinical practice guideline for emergency department ketamine dissociative sedation: 2011 update. Ann Emerg Med. 2011; 57:449–461.

22. Wood MN, Manley MC, Bezzina N, Hassan R. An audit of the use of intravenous ketamine for paediatric dental conscious sedation. Br Dent J. 2015; 218:573–577.

23. Krauss B, Green SM. Sedation and analgesia for procedures in children. N Engl J Med. 2000; 342:938–945.

24. Haas DA, Harper DG. Ketamine: A review of its pharmacologic properties and use in ambulatory anesthesia. Anesth Prog. 1992; 39:61–68.

25. Green SM, Johnson NE. Ketamine sedation for pediatric procedures: Part 2, review and implications. Ann Emerg Med. 1990; 19:1033–1046.

26. Wood M. The use of intravenous midazolam and ketamine in paediatric dental sedation. SAAD Dig. 2013; 29:18–30.

27. Bhana N, Goa KL, McClellan KJ. Dexmedetomidine. Drugs. 2000; 59:263–268. discussion 269-70.

28. Venn RM, Bradshaw CJ, Spencer R, Brealey D, Caudwell E, Naughton C, et al. Preliminary UK experience of dexmedetomidine, a novel agent for postoperative sedation in the intensive care unit. Anaesthesia. 1999; 54:1136–1142.

29. Dyck JB, Maze M, Haack C, Azarnoff DL, Vuorilehto L, Shafer SL. Computer-controlled infusion of intravenous dexmedetomidine hydrochloride in adult human volunteers. Anesthesiology. 1993; 78:821–828.

30. Bhana N, Goa KL, McClellan KJ. Dexmedetomidine. Drugs. 2000; 59:263–268. discussion 269-70.

31. Virtanen R, Savola JM, Saano V, Nyman L. Characterization of the selectivity, specificity and potency of medetomidine as an alpha 2-adrenoceptor agonist. Eur J Pharmacol. 1988; 150:9–14.